Dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
=== Kinetics === The two forms of inorganic arsenic, reduced (trivalent As(III)) and oxidized (pentavalent As(V)), can be absorbed and accumulated in tissues and body fluids. In the liver, the metabolism of arsenic involves enzymatic and non-enzymatic methylation; the most frequently excreted metabolite (≥ 90%) in the urine of mammals is dimethylarsinic acid or cacodylic acid, DMA(V). Dimethylarsenic acid is also known as Agent Blue and was used as herbicide in the American war in Vietnam. In humans, inorganic arsenic is reduced nonenzymatically from pentoxide to trioxide, using glutathione, or it is mediated by enzymes. Reduction of arsenic pentoxide to arsenic trioxide increases its toxicity and bioavailability. Methylation occurs through methyltransferase enzymes. S-adenosylmethionine (SAM) may serve as a methyl donor. Various pathways are used, the principal route being dependent on the current cellular environment. Resulting metabolites are monomethylarsonous acid, MMA(III), and dimethylarsinous acid, DMA(III). Methylation had been regarded as a detoxification process, but reduction from +5 As to +3 As may be considered as a bioactivation instead. Another suggestion is that methylation might be a detoxification if "As[III] intermediates are not permitted to accumulate" because the pentavalent organoarsenics have a lower affinity to thiol groups than inorganic pentavalent arsenics. Gebel (2002) stated that methylation is a detoxification through accelerated excretion.
== Properties == These enzymes are acid proteases; eqolisin for example is most active at pH 2.0 when casein is used as substrate. Eqolosins prefer bulky amino acid residues at the P1 site and small amino acid residues at the P1′ site. A characteristic of the protease is its insensitivity to pepstatin and S-PI (acetyl pepstatin) and it was previously classed as "pepstatin-insensitive carboxyl proteinases". The other "pepstatin-insensitive carboxyl proteinases" belongs to subfamily of serine protease, serine-carboxyl protease (sedolisin) which was discovered in 2001. These proteases are also not inhibited by DAN (diazoacetyl-DL-norleucine methylester) (7) but may be inhibited by EPNP (1,2-epoxy-3-(p-nitrophenoxy) propane).
The scope of pharmacodynamics is the effects caused on the body by a medicine. The distribution of any pharmacologic agent, its concentration in tissues, blood or plasma, and its clearance from the body, are the pharmacokinetic features of a medicine. Unlike single-agent anesthesia, which can lead to increased adverse effects when higher doses of a single drug are administered, balanced anesthesia allows for the use of lower doses of multiple agents. This strategy minimizes the risk of side effects by enabling the anesthesiologist to target specific effects through the adjustment of individual agents. The pharmacodynamics of each agent—their effects on the body—can be finely controlled, while pharmacokinetics—how these agents are distributed and cleared from the body—plays a critical role in the effectiveness of the anesthesia. Injectable anesthetic agents may be administered by constant rate infusion (CRI) which is a portion of balanced anesthetic techniques, can be made like a single intermittent dose or as a single injection. It should keep a during the time. Both the foreseeable pharmacodynamic effects and foreseeable concentration of plasma can be offered by the CRI of specific medicine. It has similarity on keeping the invariable concentration of end-tidal by using the vaporous precise device, which can provide the volatile anesthetic. When the administration rate exceeds the clearance rate, a stable-state concentration has been achieved by delivering the medicine as a CRI.
=== Transgenic plant and animals === In recent years, expression vectors have been used to introduce specific genes into plants and animals to produce transgenic organisms, for example in agriculture it is used to produce transgenic plants. Expression vectors have been used to introduce a vitamin A precursor, beta-carotene, into rice plants. This product is called golden rice. This process has also been used to introduce a gene into plants that produces an insecticide, called Bacillus thuringiensis toxin or Bt toxin which reduces the need for farmers to apply insecticides since it is produced by the modified organism. In addition expression vectors are used to extend the ripeness of tomatoes by altering the plant so that it produces less of the chemical that causes the tomatoes to rot. There have been controversies over using expression vectors to modify crops due to the fact that there might be unknown health risks, possibilities of companies patenting certain genetically modified food crops, and ethical concerns. Nevertheless, this technique is still being used and heavily researched. Transgenic animals have also been produced to study animal biochemical processes and human diseases, or used to produce pharmaceuticals and other proteins. They may also be engineered to have advantageous or useful traits. Green fluorescent protein is sometimes used as tags which results in animal that can fluoresce, and this have been exploited commercially to produce the fluorescent GloFish.
=== Unilever === In 1989, Unilever acquired Biocon Biochemicals Ltd. in Ireland and merged it with its subsidiary Quest International. Unilever later sold its holdings to the Indian owners of Biocon Limited in 1998, effectively reuniting the partnered corporations.
Sources: en.wikipedia.org
Fascia training describes sports activities and movement exercises that attempt to improve the functional properties of the muscular connective tissues in the human body, such as tendons, ligaments, joint capsules and muscular envelopes. Also called fascia, these tissues take part in a body-wide tensional force transmission network and are responsive to training stimulation. As of 2018 the body-wide continuity of this tensional system has been expressed in an educational manner within the Fascial Net Plastination Project. The FNPP brought together experts in anatomy, dissection, and plastination, and it was the first project of its kind to plastinate a complete human fascia specimen.
Transurethral resection of the prostate (TURP) replaced radical prostatectomy for symptomatic relief of obstruction in the middle of the 20th century because it could better preserve penile erectile function. Radical retropubic prostatectomy was developed in 1983 by Patrick Walsh. In 1941, Charles B. Huggins published studies in which he used estrogen to oppose testosterone production in men with metastatic prostate cancer. This discovery of "chemical castration" won Huggins the 1966 Nobel Prize in Physiology or Medicine. The role of the gonadotropin-releasing hormone (GnRH) in reproduction was determined by Andrzej W. Schally and Roger Guillemin, who both won the 1977 Nobel Prize in Physiology or Medicine for this work. GnRH receptor agonists, such as leuprorelin and goserelin, were subsequently developed and used to treat prostate cancer. Radiation therapy for prostate cancer was first developed in the early 20th century and initially consisted of intraprostatic radium implants. External beam radiotherapy became more popular as stronger X-ray radiation sources became available in the middle of the 20th century. Brachytherapy with implanted seeds (for prostate cancer) was first described in 1983. Systemic chemotherapy for prostate cancer was first studied in the 1970s. The initial regimen of cyclophosphamide and 5-fluorouracil was quickly joined by multiple regimens using a host of other systemic chemotherapy drugs.
=== Transcranial direct current stimulation === A 2016 meta-analysis of transcranial direct current stimulation (tDCS) reported some efficacy of tDCS in the treatment of acute depressive disorder with moderate effect size, and low efficacy in treatment-resistant depression, and that use of 2 mA current strength over 20 minutes per day over a short time span can be considered safe.
=== Main === Kathy Bates as Madeline "Matty" Matlock / Madeline Kingston, who claims to be a widowed lawyer, returning to the workforce following decades of retirement due to financial distress from her husband's gambling troubles, and having to raise her grandson following her daughter's death in a car accident. Matlock takes a job as an associate at the law firm Jacobson Moore, working with Olympia, a junior partner at the firm who becomes her boss. In fact, Kingston is wealthy and happily married, though indeed grieving the loss of her daughter who died from an opioid overdose and seeking retribution. She gave herself the alias of "Matlock" after the original television series. Skye P. Marshall as Olympia Lawrence, a junior partner at Jacobson Moore who becomes Matlock's boss. In the pilot episode, she is in the midst of divorcing Julian while aiming at a senior partner role with the support of her father-in-law. Olympia is reluctant to take Matty under her wing as she acknowledges that Matty is the threat to her promotion in the law firm due to her exceptional skills. Jason Ritter as Julian Markston, a senior partner at Jacobson Moore. In the pilot episode, he is in the midst of divorcing Olympia and engaged in a major settlement action involving a large pharmaceutical corporation. David Del Rio as Billy Martinez (seasons 1–2), a first-year associate at Jacobson Moore working with Olympia. Del Rio makes his last appearance in episode 7 of the second season following his dismissal from the series.
== Signs and symptoms == Often, every joint in a patient with arthrogryposis is affected; in 84% all limbs are involved, in 11% only the legs, and in 4% only the arms are involved. Every joint in the body, when affected, displays typical signs and symptoms: for example, the shoulder (internal rotation); wrist (volar and ulnar); hand (fingers in fixed flexion and thumb in palm); hip (flexed, abducted and externally rotated, frequently dislocated); elbow (extension and pronation) and foot clubfoot and less commonly congenital vertical talus. Range of motion can be different between joints because of the different deviations. Some types of arthrogryposis like amyoplasia have a symmetrical joint/limb involvement, with normal sensations. The contractures in the joints can result in delayed walking development in the first five years, but severity of contractures do not necessarily predict eventual walking ability or inability. Intelligence is normal to above normal in children with amyoplasia, but it is not known how many of these children have an above-normal intelligence, and there is no literature available about the cause of this syndrome. There are a few syndromes like the Freeman–Sheldon and Gordon syndrome, which have craniofacial involvement. The amyoplasia form of arthrogryposis is sometimes accompanied with a midline facial hemangioma. Arthrogryposis is not a diagnosis but a clinical finding, so this disease is often accompanied with other syndromes or diseases. These other diagnoses could affect any organ in a patient.
Sources: en.wikipedia.org
This series of lists omits periods from acronyms and initialisms. It uses periods for certain abbreviations that traditionally often have them (mostly older Latin/Neo-Latin abbreviations). For example, both bid and b.i.d. may be found in the list. It generally uses the singular form of an abbreviation (not the plural) as the headword. This list uses significant capitalization for headwords (the abbreviations) and their expansions.
In India's eyes, the United States would once again be regarded as untrustworthy." The Trump administration avoided sanctioning India for the Russian S-400 missile system, but sanctioned Turkey and China for the same purchases. President Trump has grown closer to India's BJP government, which shares the similar right-wing views, he has repeatedly praised Modi's leadership and avoided any negative criticism of the Indian government's actions on the citizenship and Kashmir disputes. The Trump administration is consistent with the Modi administration in combating "radical Islamic terrorism", and the US reiterates its support for India's elimination of terrorist training camp in Pakistan. In early 2020, India provided its agreement for terminating an export embargo on a medicinal drug known as hydroxychloroquine amidst the combat against the ongoing coronavirus (COVID-19) pandemic, after Trump threatened retaliation against India, if it did not comply with terminating the export embargo on hydroxychloroquine. In June 2020, during the George Floyd protests, the Mahatma Gandhi Memorial in Washington, D.C., was vandalised by unknown miscreants on the intervening night of June 2 and 3. The incident prompted the Indian Embassy to register a complaint with law enforcement agencies. Taranjit Singh Sandhu, the Indian Ambassador to the United States called the vandalism "a crime against humanity". U.S. President Donald Trump called the defacement of Mahatma Gandhi's statue a "disgrace".
Electron transfers Electron transfer (ET) between metal ions can occur via two distinct mechanisms, inner and outer sphere electron transfers. In an inner sphere reaction, a bridging ligand serves as a conduit for ET. (Degenerate) ligand exchange One important indicator of reactivity is the rate of degenerate exchange of ligands. For example, the rate of interchange of coordinate water in [M(H2O)6]n+ complexes varies over 20 orders of magnitude. Complexes where the ligands are released and rebound rapidly are classified as labile. Such labile complexes can be quite stable thermodynamically. Typical labile metal complexes either have low-charge (Na+), electrons in d-orbitals that are antibonding with respect to the ligands (Zn2+), or lack covalency (Ln3+, where Ln is any lanthanide). The lability of a metal complex also depends on the high-spin vs. low-spin configurations when such is possible. Thus, high-spin Fe(II) and Co(III) form labile complexes, whereas low-spin analogues are inert. Cr(III) can exist only in the low-spin state (quartet), which is inert because of its high formal oxidation state, absence of electrons in orbitals that are M–L antibonding, plus some "ligand field stabilization" associated with the d3 configuration. Associative processes Complexes that have unfilled or half-filled orbitals are often capable of reacting with substrates. Most substrates have a singlet ground-state; that is, they have lone electron pairs (e.g., water, amines, ethers), so these substrates need an empty orbital to be able to react with a metal centre.
A membrane transport protein is a membrane protein involved in the movement of ions, small molecules, and macromolecules such as another protein, across a biological membrane. Transport proteins are integral transmembrane proteins, that is: they exist permanently within and span the membrane, across which they transport substances. The proteins may assist in the movement of substances by facilitated diffusion, active transport, osmosis, or reverse diffusion. The two main types of proteins involved in such transport are broadly categorized as either channels or carriers (a.k.a. permeases or transporters). Examples of channel/carrier proteins include the GLUT 1 uniporter, sodium channels, and potassium channels. The solute carriers and atypical SLCs are secondary active or facilitative transporters in humans. Collectively membrane transporters and channels are known as the transportome. Transportomes govern cellular influx and efflux of, not only ions and nutrients, but drugs as well.
Chell can pick up weighted storage cubes and use them to climb or hold down large buttons that activate doors and other mechanisms. Particle fields known as "Emancipation Grills" appear at the ends of test chambers and in other locations; passing through them removes active portals and destroys objects carried through them. The fields also prevent the player from firing portals through them. Chell is equipped with mechanical heel springs that reduce the effects of falling, but she can still be killed by hazards including automated turrets, energy projectiles, toxic liquid, falling objects, and crushing mechanisms. The game does not display a conventional health bar; instead, Chell dies after sustaining sufficient damage within a short period. Certain hazards, including some energy projectiles and crushing mechanisms, can kill her immediately. The test chambers can be completed through different solutions, with players able to use the portal mechanics and physics in different ways to overcome the puzzles. After completing the main game, two additional modes become available: Challenge Chambers and Advanced Chambers. Challenge Chambers revisit existing test chambers with additional objectives based on completing them with the fewest portals, the fewest footsteps, or the shortest time. Advanced Chambers modify existing chambers by adding obstacles and other hazards.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.